目的:评价西咪匹韦治疗基因1型丙型肝炎的疗效和安全性。方法:检索EMBASE、PubMed、The Cochrane Central Register of Controlled Trials、clinicaltrials.gov、CNKI全文数据库、万方数据库中关于西咪匹韦治疗基因1型丙型肝炎的疗效和安全性的随机对照试验,检索起始日期为2000年1月1日,截止时间为2016年8月8日。采用RevMan5.3对纳入的研究进行Meta分析。结果:共7项研究符合纳入标准入选本Meta分析,共纳入2 301例患者。分析结果显示西咪匹韦快速病毒学应答(RVR)、持续早期病毒应答(SVR12)、持续病毒学应答(SVR24)等获得率均明显高于对照组(P<0.000 1),病毒复发率明显低于对照组(P<0.000 1);100 mg组西咪匹韦RVR,SVR12,SVR24,病毒复发率等指标明显优于对照组(P<0.001),而150 mg组除了SVR24与对照组对比,差异无统计学意义外(P>0.05),其余指标均优于对照组(P<0.001)。西咪匹韦组一般不良反应发生率与对照组相比,差异无统计学意义(P>0.05),与临床治...
【英文摘要】
OBJECTIVE To evaluate the efficiency and safety of simeprevir in treatment of genotype 1 hepatitis C.METHODS Different databases were searched,including EMBASE,PubMed and Cochrane Central Register of randomized controlled trial,clinicaltrials.gov,Chinese full text database,CNKI,Wanfang database.Meta analysis was performed by using RevMan5.3.RESULTS A total of 7 studies including2 301 patients met the inclusion criteria.Compared to control group,RVR,SVR12 and SVR24of simeprevir were significantly higher(P<0....